Heron Therapeutics reports Q3 2025 net revenue of $38.2 million

Reuters

2025/11/04

Heron <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 2025 net revenue of $38.2 million

Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580317177"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580317177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580317177?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580317177","market":"fut","top_or_hot":-1,"title":"Heron Therapeutics reports Q3 2025 net revenue of $38.2 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heron <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports Q3 2025 net revenue of $38.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/HRTX\">Heron Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heron Therapeutics reports Q3 2025 net revenue of $38.2 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeron Therapeutics reports Q3 2025 net revenue of $38.2 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heron <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports Q3 2025 net revenue of $38.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/HRTX\">Heron Therapeutics Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL7HRQ4c:1","article_id":"2580317177","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580317177","pubTimestamp":1762261244,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","HRTX":"Heron Therapeutics Inc."},"translate_title":"Heron Therapeutics报告2025年第三季度净收入为3820万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRTX":0.9,"NDAQ":0.9},"content_text":"Heron Therapeutics reports Q3 2025 net revenue of $38.2 million\n    \n\n        Heron Therapeutics reported net revenue of $38.2 million for the third quarter of 2025, bringing year-to-date net revenue to $114.3 million, a 10.4% increase compared to the prior year period. The company reaffirmed its 2025 full-year net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million. ZYNRELEF net revenue grew 49% in the third quarter of 2025 compared to the same period in 2024, supported by the launch of the Vial Access Needle and an enhanced distributor incentive program. APONVIE net revenue increased 173% year-over-year for the quarter, driven by expanded adoption and a newly launched dedicated sales team. The Acute Care franchise achieved 67.2% revenue growth year-over-year in the third quarter and 69.2% growth for the first nine months of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568238-en) on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}